Bridgefront Capital’s Seres Therapeutics MCRB Stock Holding History

Bridgefront Capital’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-518	Closed	-$58K	–	514
2022 Q4	$58K	Buy	+518	New	+$69.4K	0.04%	348

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bridgefront Capital's MCRB Position: Q1 2023 in Review

Bridgefront Capital sold out of Seres Therapeutics (MCRB) in Q1 2023, closing a stake of 518 shares — an estimated $58K sold.

Bridgefront Capital first reported a position in MCRB in Q4 2022 and held it in 1 quarter. The position peaked at $58K in Q4 2022. 123 funds tracked by Wall St. Rank hold MCRB as of Q1 2023.

Bridgefront Capital reported no remaining Seres Therapeutics position as of Q1 2023 after selling out during the quarter.
Bridgefront Capital sold 518 Seres Therapeutics shares in Q1 2023, an estimated $58K.
Bridgefront Capital first reported a position in Seres Therapeutics in Q4 2022 and held it in 1 quarter.
Bridgefront Capital's Seres Therapeutics position peaked at $58K in Q4 2022.
123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2023.

Based on Bridgefront Capital's 13F filing for Q1 2023, filed 15 May 2023.